Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

目的 研究嵌合型CD25单抗治疗造血干细胞移植术后激素耐药的急性移植物抗宿主病(GVHD)的疗效.方法 2005年3月至2007年7月诊断急性GVHD的患者36例,在1～2 mg/ks的肾上腺皮质激素治疗无效后,应用静脉注射嵌合型CD25单抗治疗.结果 总有效率为83.3%(30/36),其中完伞缓解率69.4%(25/36),部分缓解率13.9%(5/36).单因素分析显示疗效与GVHD分度及配型相合程度相关,与累及器官数量无关.患者生存情况与配型情况、GVHD分度及累及器官数量无关.结论 嵌合型CD25单克隆抗体是治疗造血干细胞移植术后肾上腺皮质激素耐药的急性GVHD的有效药物.To investigate the efficacy of chimeric anti-CD(25) monoclonal antibody (basiliximab) on acute graft-versus-host disease (GVHD) in patients following allogeneic hematopoietic stem cell transplantation.Thirty-six patients who were suffered from acute GVHD from March 2005 to July 2007 were studied. All of them were treated with steroid first and got no response, then began basiliximab therapy.Thirty of 36 patients showed response to basiliximab therapy including 25 complete responses and 5 partial responses. The efficacy was associated with the degree of GVHD and the source of donor.Patients suffered from steroid-resistant acute GVHD can be successfully treated with basiliximab.国家自然科学基金PubMed中文核心期刊要目总览(PKU)中国科技核心期刊(ISTIC)中国科学引文数据库(CSCD)011923-9254